KRAS and cancer: Based on the sensitivity to BI-2493 observed in KRAS WT–amplified cancer cell lines, we suggest expanding the range of KRAS alterations that can be targeted with a pan-KRAS inhibitor and to include KRAS WT–amplified tumors.